Pallas vs Hims & Hers: GLP-1 Telehealth Compared

Hims & Hers is one of the largest telehealth brands in the US and rolled out their Weight Loss by Hims program in 2024 — quickly becoming one of the most-searched GLP-1 telehealth options. Pallas Health is a newer alternative focused specifically on compounded GLP-1 weight loss care. Both ship semaglutide to your door. Here's what's actually different.

Quick comparison

What Hims does well

Scale and brand recognition. Hims & Hers is a public company (NYSE: HIMS) with millions of customers across their broader telehealth stack. The brand is familiar; the app and billing infrastructure are polished; the customer support team is large.

Cross-vertical convenience. If you're already on Hims for hair loss, ED, or mental health, adding their weight loss program into the same app is genuinely easy. Single login, single billing relationship.

Consistent pricing tiers. Hims has publicly stated their intention to hold compounded GLP-1 pricing in a specific range, and they've maintained roughly consistent pricing across their program launch.

Marketing and content ecosystem. Hims has extensive educational content, community features, and app-based tracking. For patients who want a more product-experience-heavy platform, this matters.

What Pallas does differently

Single-category focus on weight loss. Pallas isn't a men's health company that added GLP-1 — it's a GLP-1-only telehealth company. For patients who want to be a priority (not one of a dozen verticals), the focus shows up in provider responsiveness, medication breadth within the category, and program design.

Three GLP-1 formats. Pallas offers compounded semaglutide as both an injection and a daily oral tablet, plus compounded tirzepatide injection. Hims's compounded program is primarily injection-based.

Flat, transparent pricing. Both Pallas and Hims list similar base pricing, but Pallas's structure is designed to be simpler — one number per medication, month to month, everything included. Hims has multiple program tiers, and patients occasionally report surprise charges at dose increases or during brand-name switches.

Direct line to support. Pallas is smaller and deliberately so. Support messages get human responses within hours; founders are reachable. Hims is large enough that support routes through tiered queues.

Pricing: the real comparison

Both brands publish similar starting prices, but the structures differ in a few important ways.

Compounded semaglutide (monthly)

• Pallas: a flat $269/mo. Includes intake, provider, medication, shipping, unlimited messaging
• Hims: Starting at $199/month on introductory offers; $299/month for the compounded weight loss program at standard rates. Pricing structure has varied over program launch period

First year total (estimated):

• Pallas: $269/mo × 12 = about $3,200
• Hims: $199 + ($299 × 11) = $3,488 (or less with intro promotions)

Essentially within a few dollars of each other at current pricing. Neither is meaningfully cheaper than the other on compounded.

Brand-name Wegovy® or Zepbound®

Both platforms can prescribe brand-name. Pricing for the medication itself is set by the pharmaceutical company (Novo Nordisk or Eli Lilly) and runs $1,100–1,400/month regardless of telehealth provider. Insurance coverage — if you have it — is what drives the actual cost down.

Neither platform materially changes brand-name pricing. The difference is workflow — how smoothly they handle prior authorization, how clearly they communicate pharmacy delays, how quickly providers respond.

The hidden cost differential

Across both platforms, the most impactful hidden cost is how much time you lose to friction. Delayed shipments, stuck prior auths, slow provider responses — these add up to real time and occasionally force emergency fills at other pharmacies.

Pallas optimizes aggressively for response time on these fronts because they're a smaller company with fewer verticals. Hims has more support capacity in total but slower per-ticket resolution due to volume.

Product experience differences

Intake and qualification

Both platforms use a standard online intake (5–10 minutes) followed by provider review. Hims's intake is tied to their broader app, so you can later easily add other verticals. Pallas's intake is focused exclusively on GLP-1 weight management, with a more clinical tone.

Qualification decisions typically arrive within 1 business day on both platforms.

Provider experience

Hims providers are W-2 or contract physicians and NPs across their extensive network. With a platform at Hims's scale, you're relatively unlikely to see the same provider on repeat visits. This is fine for simple dose management but less personal.

Pallas works with a smaller provider group (via a telehealth partner platform) and patients often build a longer-term relationship with the same provider. For patients managing complex comorbidities or titration issues, this continuity matters.

App and tracking

Hims has a more developed app ecosystem — progress tracking, photo logging, optional coaching features, integration with other Hims programs. If you value app-based engagement, this is real.

Pallas is deliberately more straightforward — a web-first experience focused on the medication relationship. No habit-building curriculum, no photo tracking, just the medication and the messaging channel to your provider.

Pharmacy and shipping

Both platforms use US-licensed pharmacies for compounded medications. Shipping times are similar (2–5 business days), and both ship in discreet packaging. No material difference here.

Who should pick which

Hims is probably the better fit if:

• You're already a Hims customer for other products (hair, ED, mental health)
• You want a polished, app-driven experience with tracking and community features
• Brand familiarity is important to you
• You prefer a larger platform with broad vertical coverage

Pallas is probably the better fit if:

• You want a focused, medication-first experience without cross-selling
• You value direct provider relationships over app features
• You want to work with a smaller team where you're more visible as a patient
• You prefer multiple GLP-1 formats (injection or oral) at a flat per-medication price
• You're evaluating multiple options and care about transparent pricing without tier complexity

Either works well if:

• You just want compounded GLP-1 shipped to your door at around $300/month
• You have realistic expectations about what telehealth GLP-1 care covers

For a deeper pricing breakdown, see how much semaglutide costs without insurance. For the clinical side-effect and titration experience that applies regardless of platform, see our first 3 months guide.

Switching between platforms

Both platforms support clean transitions. If you're currently on Hims and want to switch to Pallas (or vice versa):

1. Export your prescription history from the current platform (available in patient portal)
2. Complete the new platform's intake, noting your current medication and dose
3. Provider reviews and either continues your existing dose or adjusts
4. Typical continuity: no restart of titration needed if you're not off medication for more than 4 weeks

Frequently asked questions

Is Hims cheaper than Pallas? Not meaningfully. Both are in the same ~$3,500/year range for compounded. Hims has had more aggressive introductory promotions historically; Pallas's pricing is flat and doesn't rely on promotions.

Is Hims better for women specifically? Hims launched as a men's health brand (Hims) and added Hers for women; their platform supports both. Pallas serves both men and women equally — there's no meaningful gender-specific difference in the weight loss program itself.

Can I use both platforms at the same time? You could, but you shouldn't. Different providers with different prescriptions means you risk dose conflicts and insurance issues. Pick one for GLP-1 therapy. It's fine to use one for weight loss and another for unrelated conditions.

Which has better doctors? Both use licensed US providers and both are required to provide board-certified practitioners in your state. There's no reliable data showing one platform has consistently better clinical outcomes.

Does Hims have tirzepatide? Yes, Hims added compounded tirzepatide to their program in 2024. Both Pallas and Hims offer both compounded semaglutide and tirzepatide.

Is Pallas too small to be reliable? Pallas is newer than Hims, objectively. What that means depends on what you value: fewer customers ahead of you in line (faster responses, more attention) vs. less operational track record. Both are real considerations. Hims's scale is reassuring to some patients and impersonal to others.

Bottom line: Hims is the bigger brand with a broader product suite and polished app experience. Pallas is focused on compounded GLP-1 weight care, with three medication formats and flat per-medication pricing. At similar pricing on injection semaglutide, the choice comes down to whether you want a more product-polish experience (Hims) or a more medication-focused experience (Pallas).